Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Janssens, R.M.J.
Right arrow Articles by Schoemaker, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janssens, R.M.J.
Right arrow Articles by Schoemaker, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 15, No. 11, 2333-2340, November 2000
© 2000 European Society of Human Reproduction and Embryology

Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study

R.M.J. Janssens, C.B. Lambalk1, J.P.W. Vermeiden, R. Schats, J.M. Bernards, L.T.M. Rekers-Mombarg and J. Schoemaker

Research Institute for Endocrinology, Reproduction and Metabolism, IVF Center, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study to determine the minimal daily dose of triptorelin acetate needed to suppress a premature LH surge during IVF treatment in a long protocol. A total of 240 women (60 in each group) was randomized to either placebo or to one of three doses of triptorelin, i.e. 15, 50 or 100 µg daily. Ovarian stimulation was performed with two or three ampoules of FSH daily. A premature LH surge occurred in 23% of placebo-treated patients, but in none of the triptorelin acetate-treated patients. There were significantly more oocytes and embryos in the 50 and 100 µg triptorelin groups. There was no dose relationship in rates of either implantation, pregnancy, ongoing pregnancy, live birth or baby take-home. In this study we showed that daily administration of 15 µg triptorelin is sufficient to prevent a premature LH surge, and that 50 µg is equivalent to 100 µg in terms of IVF results.

Key words: dose reduction/IVF/LH surge/triptorelin

1 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Free University Hospital, IVF Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. E-mail: cb.lambalk{at}azvu.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
K. Jayaprakasan, B.K. Campbell, J.F. Hopkisson, J.S. Clewes, I.R. Johnson, and N.J. Raine-Fenning
Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone
Hum. Reprod., November 1, 2008; 23(11): 2577 - 2583.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Jayaprakasan, J.F. Hopkisson, B.K. Campbell, J. Clewes, I.R. Johnson, and N.J. Raine-Fenning
Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response
Hum. Reprod., July 1, 2008; 23(7): 1538 - 1544.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. NyboeAndersen, P. Humaidan, G. Fried, J. Hausken, L. Antila, S. Bangsboll, P.E. Rasmussen, S. Lindenberg, H. E. Bredkjaer, H. Meinertz, et al.
Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial
Hum. Reprod., February 1, 2008; 23(2): 427 - 434.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. Safdarian, F. S. Mohammadi, A. Alleyassin, M. Aghahosseini, A. Meysamie, and E. Rahimi
Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916)
Hum. Reprod., September 1, 2007; 22(9): 2449 - 2454.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
G. H. Trew
Comparing highly purified hMG and rFSH in patients undergoing IVF
Hum. Reprod., June 1, 2007; 22(6): 1797 - 1798.
[Full Text] [PDF]


Home page
Hum ReprodHome page
A. N. Andersen, P. Devroey, and J.-C. Arce
Reply: Comparing highly purified hMG and rFSH in patients undergoing IVF
Hum. Reprod., June 1, 2007; 22(6): 1798 - 1800.
[Full Text] [PDF]


Home page
Hum ReprodHome page
C. B. Lambalk and R. Homburg
GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution
Hum. Reprod., October 1, 2006; 21(10): 2580 - 2582.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
I.E. Messinis, D. Loutradis, E. Domali, C.P. Kotsovassilis, L. Papastergiopoulou, A. Kallitsaris, P. Drakakis, K. Dafopoulos, and S. Milingos
Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment
Hum. Reprod., November 1, 2005; 20(11): 3192 - 3197.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.-C. Arce, A. Nyboe Andersen, and J. Collins
Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review
Hum. Reprod., July 1, 2005; 20(7): 1757 - 1771.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk
Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy
Hum. Reprod., February 1, 2005; 20(2): 359 - 367.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. H. Yu Ng, C. Chi Wai Chan, O. S. Tang, W. Shu Biu Yeung, and P. Chung Ho
Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation
Hum. Reprod., December 1, 2004; 19(12): 2811 - 2815.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. Dal Prato, A. Borini, G. Coticchio, M. Cattoli, and C. Flamigni
Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study
Hum. Reprod., October 1, 2004; 19(10): 2200 - 2205.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk
Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels
Hum. Reprod., October 1, 2004; 19(10): 2206 - 2215.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. Balasch, E. Vidal, J. Penarrubia, R. Casamitjana, F. Carmona, M. Creus, F. Fabregues, and J. A. Vanrell
Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH
Hum. Reprod., August 1, 2001; 16(8): 1636 - 1643.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L.D. Prato, A. Borini, M.R. Trevisi, M.A. Bonu, E. Sereni, and C. Flamigni
Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study
Hum. Reprod., July 1, 2001; 16(7): 1409 - 1414.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.